戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 everal azoles but higher susceptibilities to isavuconazole.
2 ll forms of aspergillosis is voriconazole or isavuconazole.
3  with the greatest variability observed with isavuconazole.
4 t active azole was posaconazole, followed by isavuconazole.
5 onazole, 0.5 ug/mL; posaconazole, 0.5 ug/mL; isavuconazole, 1 ug/mL; ketoconazole, bimodal, no ECV de
6                          Patients were given isavuconazole 200 mg (as its intravenous or oral water-s
7        Adult patients were randomized 1:1 to isavuconazole (200 mg intravenous [IV] three-times-daily
8  1 mug/ml), posaconazole (0.5 and 1 mug/ml), isavuconazole (4 and 4 mug/ml), and amphotericin B (0.25
9 o day 42 for the ITT population was 19% with isavuconazole (48 patients) and 20% with voriconazole (5
10                                     Overall, isavuconazole activity (92.7%/94.0% WT in EU/NA) was com
11                     Thirty patients received isavuconazole after a median of 65 days on another thera
12  assumption explains the superior potency of isavuconazole against A. castellanii The dimerization mo
13 enzyme would explain the superior potency of isavuconazole against A. castellanii.
14                            The activities of isavuconazole against the larger collection of Candida s
15          We report the MIC distributions for isavuconazole and 111 isolates of Candida (42 Candida al
16 ere reported in 109 (42%) patients receiving isavuconazole and 155 (60%) receiving voriconazole (p<0.
17           Most patients (247 [96%] receiving isavuconazole and 255 [98%] receiving voriconazole) had
18 B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet
19                 We evaluated the activity of isavuconazole and other mold-active azoles against 731 A
20                                         Both isavuconazole and voriconazole are first-line agents in
21                                 We performed isavuconazole and voriconazole broth microdilution susce
22 e compared effectiveness and tolerability of isavuconazole and voriconazole prophylaxis in lung trans
23 netic analysis of cyp51 genes confirmed that isavuconazole and voriconazole susceptibility testing id
24                                              Isavuconazole and voriconazole were discontinued prematu
25 umigatus against voriconazole, posaconazole, isavuconazole, and itraconazole using the cyp51A genotyp
26                                Voriconazole, isavuconazole, and posaconazole also demonstrated good i
27                                Itraconazole, isavuconazole, and terbinafine had higher MIC values aga
28  (the SOTIS [Solid Organ Transplantation and ISavuconazole] and DiasperSOT [DIagnosis of ASPERgillosi
29                                              Isavuconazole appears to be a well-tolerated treatment.
30 IVT was observed in 60.3% of patients in the isavuconazole arm and 71.1% in the caspofungin arm (adju
31 patients could switch to oral isavuconazole (isavuconazole arm) or voriconazole (caspofungin arm).
32 (88% mucormycetes, Aspergillus) who received isavuconazole as primary (n = 33) or salvage (n = 17) th
33              Mucormycosis cases treated with isavuconazole as primary treatment were matched with con
34 sting at a MIC of 0.5 mg/L (susceptible) but isavuconazole at 2 mg/L (intermediate).
35 P51 adopted a typical CYP monomer structure, isavuconazole-bound AcCYP51 failed to refold 74 N-termin
36                                              Isavuconazole can be used for treatment of mucormycosis
37 ality in seven (33%) of 21 primary-treatment isavuconazole cases was similar to 13 (39%) of 33 amphot
38                               In the AcCYP51-isavuconazole complex, the protein target failed to refo
39                                              Isavuconazole demonstrates broad-spectrum activity again
40       Most common causes of voriconazole and isavuconazole discontinuation were hepatotoxicity and la
41 atment-emergent adverse events and premature isavuconazole discontinuation.
42 le invasive mold disease (IMD) that received isavuconazole for >=24 h as first-line or salvage therap
43  We included 81 SOT recipients that received isavuconazole for a median of 58.0 days because of invas
44 2013, 37 patients with mucormycosis received isavuconazole for a median of 84 days (IQR 19-179, range
45 mphotericin, he was treated effectively with isavuconazole for over 6 months despite ongoing treatmen
46 retrospective study of patients treated with isavuconazole for proven or probable CA between 2014 and
47               Our results support the use of isavuconazole for the primary treatment of patients with
48       We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared
49  agents in treatment guidelines for IAI, but isavuconazole has favorable properties, often leading it
50                                              Isavuconazole has theoretical advantages over other mold
51               We found that voriconazole and isavuconazole have a very high essential agreement withi
52 le is known about the efficacy and safety of isavuconazole in CA.
53 ulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1
54                                              Isavuconazole is a new broad-spectrum triazole with a fa
55                                              Isavuconazole is a new extended-spectrum triazole with a
56                                              Isavuconazole is a novel triazole with broad-spectrum an
57                                              Isavuconazole is a safe therapeutic option for IMD in SO
58                                              Isavuconazole is a triazole active in vitro and in anima
59                                              Isavuconazole is an extended-spectrum triazole with in v
60                 Mortality of CA treated with isavuconazole is similar to that reported with voriconaz
61                                              Isavuconazole is unstudied as prophylaxis in organ trans
62                                              Isavuconazole (ISA) and voriconazole (VORI) are recommen
63                         Prolonged courses of isavuconazole (ISA) are increasingly utilized in immunoc
64 g posaconazole (PCZ), voriconazole (VCZ), or isavuconazole (ISA) for > 5 days as PAP during RIC were
65                                              Isavuconazole (ISA) is an attractive candidate for prima
66                                              Isavuconazole (ISAV) is a novel, broad-spectrum, triazol
67                                              Isavuconazole (ISAV) is an extended spectrum mold-active
68  After day 10, patients could switch to oral isavuconazole (isavuconazole arm) or voriconazole (caspo
69  M38 broth microdilution for amphotericin B, isavuconazole, itraconazole, and posaconazole.
70             Also, the relative activities of isavuconazole, itraconazole, fluconazole, posaconazole,
71 or itraconazole, voriconazole, posaconazole, isavuconazole, ketoconazole, terbinafine, flucytosine, a
72                               When measured, isavuconazole levels were low in cerebrospinal fluid but
73                                              Isavuconazole MIC values for three mucormycete isolates
74                            Patients received isavuconazole (n = 144) or voriconazole (n = 156) for me
75 ed comparable survival in patients receiving isavuconazole or voriconazole as a first-line treatment.
76          At 1 year, 8% of patients receiving isavuconazole or voriconazole developed IFIs.
77 retrospective study of patients who received isavuconazole or voriconazole for antifungal prophylaxis
78 e study included 158 patients overall and 78 isavuconazole patients in the PK/PD modeling.
79 acodynamic (PK/PD) analysis in patients with isavuconazole plasma concentrations was conducted to est
80 azole and voriconazole; the MIC90 values for isavuconazole, posaconazole, and voriconazole against Ca
81                                              Isavuconazole remained active (MIC, <=1 mg/L) against 18
82 hotericin B, voriconazole, posaconazole, and isavuconazole, respectively.
83                                              Isavuconazole showed activity against mucormycosis with
84                                              Isavuconazole showed good activities against Cryptococcu
85      Voriconazole can be used to predict the isavuconazole susceptibility testing result when A. fumi
86 f invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amph
87 n the presence of the drugs clotrimazole and isavuconazole, the AcCYP51 drug complexes crystallized a
88 ed to result in a negative GMI at the end of isavuconazole therapy.
89 study did not demonstrate non-inferiority of isavuconazole to caspofungin for primary treatment of in
90                                              Isavuconazole toxicity led to treatment interruption in
91                                     However, isavuconazole-treated patients had a lower frequency of
92 post hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunoc
93 SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invas
94                                              Isavuconazole was administered as a first-line treatment
95 ents, respectively, and was more likely when isavuconazole was administered as first-line single-agen
96                                              Isavuconazole was compared to caspofungin followed by or
97                                              Isavuconazole was effective and well tolerated as antifu
98                                              Isavuconazole was non-inferior to voriconazole for the p
99 ive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole.
100                                              Isavuconazole was used as first-line (72.8%) or salvage
101                                              Isavuconazole was well tolerated compared with voriconaz
102 se studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few s
103 ved in the majority of patients treated with isavuconazole, with clinical failures observed only in t

 
Page Top